Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 156Neoplasms 115Colorectal Neoplasms 98Breast Neoplasms 93Pancreatic Neoplasms 81Neoplasm Metastasis 81Leukemia, Myeloid, Acute 79Recurrence 76Prostatic Neoplasms 74Ovarian Neoplasms 74Melanoma 74Multiple Myeloma 66Stomach Neoplasms 59Lung Neoplasms 56Squamous Cell Carcinoma of Head and Neck 55Triple Negative Breast Neoplasms 50Glioblastoma 49Lymphoma 47Endometrial Neoplasms 43Carcinoma, Hepatocellular 42Advanced Solid Tumor 42Lymphoma, Non-Hodgkin 41Precursor Cell Lymphoblastic Leukemia-Lymphoma 40Advanced Solid Tumors 37Small Cell Lung Carcinoma 35Uterine Cervical Neoplasms 34Carcinoma, Renal Cell 34Lymphoma, Large B-Cell, Diffuse 32Lymphoma, B-Cell 32Sarcoma 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × HER2-positive Gastric Cancer × Clear all
NCT06572319 2024-08-27

Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens

Zhejiang Cancer Hospital

Phase 1/2 Recruiting
35 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡